There are 2789 resources available
507TiP - PRESERVE 1: A phase III, randomized, double-blind trial of trilaciclib versus placebo in patients receiving FOLFOXIRI/bevacizumab for metastatic colorectal cancer
Presenter: Joleen Hubbard
Session: ePoster Display
509TiP - REPROGRAM-01, a phase II study of regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer
Presenter: Elodie Klajer
Session: ePoster Display
511TiP - A phase III, multicenter, open-label, randomized study to assess the efficacy and safety of cetuximab plus capecitabine versus cetuximab as maintenance treatment following first-line induction treatment with FOLFOX and cetuximab in Chinese patients with RAS and BRAF WT mCRC
Presenter: Dongsheng Zhang
Session: ePoster Display
521P - Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors
Presenter: Maria Vieito
Session: ePoster Display
466P - Landscape of HER2 alterations in 5786 Chinese patients with colorectal cancer
Presenter: Xiaoyun Li
Session: ePoster Display
523P - AFP-maytansine conjugate: A novel targeted cancer immunotherapy
Presenter: Igor Sherman
Session: ePoster Display
468P - Prognostic role of aspartate aminotransferase-to-alanine aminotransferase ratio and lactate dehydrogenase levels in resectable colorectal cancer
Presenter: Ma Yifei
Session: ePoster Display